Holen Sie sich die Stockscreener-App
5.05
3.48%
0.17
Handel nachbörslich:
5.37
0.32
+6.34%
Schlusskurs vom Vortag:
$4.88
Offen:
$4.91
24-Stunden-Volumen:
300.07K
Relative Volume:
1.33
Marktkapitalisierung:
$216.56M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-19.90M
KGV:
-9.5283
EPS:
-0.53
Netto-Cashflow:
$-19.80M
1W Leistung:
+20.81%
1M Leistung:
+27.85%
6M Leistung:
-19.84%
1J Leistung:
+36.86%
1-Tages-Spanne:
$4.81
$5.25
1-Wochen-Bereich:
$4.1518
$5.25
52-Wochen-Spanne:
$3.19
$6.8184
Diamedica Therapeutics Inc Stock (DMAC) Company Profile
Firmenname
Diamedica Therapeutics Inc
Sektor
Branche
Telefon
(763) 496-5454
Adresse
301 CARLSON PARKWAY, MINNEAPOLIS, MN
Vergleichen Sie DMAC mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DMAC
Diamedica Therapeutics Inc
|
5.05 | 251.27M | 0 | -19.90M | -19.80M | -0.53 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.65 | 121.28B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.10 | 60.96B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.81 | 42.77B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.99 | 36.21B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.47 | 32.08B | 3.81B | -644.79M | -669.77M | -6.24 |
Diamedica Therapeutics Inc Stock (DMAC) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-10-07 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-04-24 | Fortgesetzt | Craig Hallum | Buy |
| 2023-06-22 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2021-04-09 | Eingeleitet | Oppenheimer | Outperform |
| 2021-02-17 | Eingeleitet | ROTH Capital | Buy |
| 2020-10-30 | Eingeleitet | Guggenheim | Buy |
| 2020-07-08 | Eingeleitet | Maxim Group | Buy |
| 2019-04-30 | Eingeleitet | Dougherty & Company | Buy |
| 2019-03-05 | Eingeleitet | Lake Street | Buy |
Alle ansehen
Diamedica Therapeutics Inc Aktie (DMAC) Neueste Nachrichten
What drives DiaMedica Therapeutics Inc. stock priceRapidly growing investment returns - PrintWeekIndia
DiaMedica gains on positive mid-stage trial data for lead drug in preeclampsia - MSN
DiaMedica Therapeutics Inc. Stock Analysis and ForecastFree Market Volatility Navigation Tips - PrintWeekIndia
Is DiaMedica Therapeutics Inc. stock overhyped or has real potentialBreakthrough financial growth - jammulinksnews.com
DiaMedica raises $30.1M in private placement for preeclampsia, stroke treatment - The Business Journals
The Beat: Entrust names new CEO, DiaMedica raises millions - The Business Journals
DiaMedica Therapeutics Announces Closing of $30.1 Million Private Placement - BioSpace
DiaMedica Therapeutics Secures $30.1 Million in Private Placement - TipRanks
DiaMedica Therapeutics closes $30.1 million private placement - Investing.com India
DiaMedica Therapeutics closes $30.1 million private placement By Investing.com - Investing.com UK
Is DiaMedica Therapeutics Inc. a good long term investmentDynamic profit expansion - jammulinksnews.com
What analysts say about DiaMedica Therapeutics Inc. stockFree Stock Market Knowledge Sharing - jammulinksnews.com
Diamedica Therapeutics shares rise 11.01% intraday after $30.1M private placement and positive trial results for DM199 in preeclampsia. - AInvest
DiaMedica Therapeutics to sell 8.606M shares at $3.50 in private placement - TipRanks
DiaMedica Announces $30.1M Private Placement for DM199 - TipRanks
DiaMedica secures $30.1 million in private placement for clinical trials By Investing.com - Investing.com South Africa
DiaMedica secures $30.1 million in private placement for clinical trials - Investing.com
User - FinancialContent
DiaMedica Therapeutics (NASDAQ:DMAC) Price Target Raised to $12.00 - Defense World
DiaMedica shares drop 35% following InvestingPro’s overvalued warning By Investing.com - Investing.com India
What makes DiaMedica Therapeutics Inc. stock price move sharplyReliable High Profit Alerts - beatles.ru
DiaMedica stock price target raised to $12 from $10 at H.C. Wainwright - Investing.com
DiaMedica Therapeutics to be included in the Russell 2000 and 3000 indexes - MSN
DiaMedica Therapeutics Reports Positive Interim Phase 2 Preeclampsia Results: Statistically Significant Reductions in Blood Pressure and No Placental Transfer - BioSpace
DiaMedica Therapeutics reports interim results from DM199 study - TipRanks
DiaMedica Announces Positive Interim Results for DM199 Study - TipRanks
DiaMedica reports positive interim results for preeclampsia treatment - Investing.com
Why DiaMedica Therapeutics Inc. stock attracts strong analyst attentionVerified Return Tips - Newser
How DiaMedica Therapeutics Inc. stock performs during market volatilityValue Pick Scanner - Newser
3 Promising Penny Stocks With Market Caps Under $200M - simplywall.st
Trend Tracker for (DMAC) - news.stocktradersdaily.com
DiaMedica Therapeutics Inc.(NasdaqCM: DMAC) added to Russell 2000 Dynamic Index - MarketScreener
DiaMedica Therapeutics Inc.(NasdaqCM: DMAC) added to Russell 3000 Growth Index - MarketScreener
Finanzdaten der Diamedica Therapeutics Inc-Aktie (DMAC)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.97%
0.22%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):